首页> 外国专利> SPARC-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES AND AGENTS INDUCING IMMUNITY AGAINST CANCERS COMPRISING THE SAME

SPARC-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES AND AGENTS INDUCING IMMUNITY AGAINST CANCERS COMPRISING THE SAME

机译:SPARC衍生的肿瘤排斥抗原肽和引发免疫力的抗癌药物

摘要

It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.
机译:本发明的目的是鉴定能够诱导对肿瘤具有细胞毒活性的人杀伤性T细胞和辅助性T细胞的SPARC蛋白来源的肽,并提供对各种类型的患者进行肿瘤免疫疗法的手段。过度表达SPARC的癌症。本发明提供以下任何一种的肽:(A)由SEQ ID NO:1至3中任一项所示的氨基酸序列组成的肽;要么(B)由氨基酸序列组成的肽,该氨基酸序列相对于由SEQ ID NOS:1-3中任一项所示的氨基酸序列组成的肽,包含一个或多个氨基酸的取代或添加,并且具有诱导细胞毒性(杀伤性)T细胞的能力。

著录项

  • 公开/公告号IL195831A

    专利类型

  • 公开/公告日2012-05-31

    原文格式PDF

  • 申请/专利权人 ONCOTHERAPY SCIENCE INC.;KUMAMOTO UNIVERSITY;

    申请/专利号IL20080195831

  • 发明设计人

    申请日2008-12-10

  • 分类号C07K;

  • 国家 IL

  • 入库时间 2022-08-21 17:24:46

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号